Recent Updates
Recently added Catalysts
SMMT

Summit Therapeutics plc : Notice of Results

Key Takeaway: Accessibility: Skip TopNav Summit Therapeutics plc : Notice of Results March 27, 2017 07:00 ET Summit Therapeutics plc Summit Therapeutics plc Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS PROVIDES NOTICE OF FINANCIAL RESULTS FOR THE

Full Press Release Details

Accessibility: Skip TopNav

Summit Therapeutics plc : Notice of Results

March 27, 2017 07:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Therapeutics plc
("Summit", the "Company", or the "Group")
SUMMIT THERAPEUTICS PROVIDES NOTICE OF FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED 31 JANUARY 2017
Oxford, UK, 27 March 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2017 on Wednesday, 29 March 2017.
Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the full year results press release and a replay of the call will also be available through the Company's website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) Tel: +44 (0)1235 443 951 +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson Tel: +44 (0)20 7213 0880
N+1 Singer (Broker) Aubrey Powell / Jen Boorer Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications (US media contact) Chris Erdman / Karen Sharma Tel: +1 781 235 3060 cerdman@macbiocom.com ksharma@macbiocom.com
Consilium Strategic Communications (Financial public relations, UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville Tel: +44 (0)20 3709 5700 summit@consilium-comms.com
Last updated: Mar 27, 2017